For the year ending 2025-12-31, INDV had -$124M decrease in cash & cash equivalents over the period. -$93M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | 210 | 2 |
| Depreciation and amortization | 10 | 29 |
| Amortization of right-of-use assets | 10 | - |
| Stock-based compensation expense | 26 | 24 |
| Impairment of tangible and intangible assets | 19 | 8 |
| Unrealized loss on equity investments | 0 | -9 |
| Deferred income taxes | -46 | 6 |
| Acquired in-process research and development | 0 | 1 |
| Impact from foreign exchange movements | -1 | 2 |
| Other adjustments, net | - | 0 |
| Accounts receivable | -3 | 1 |
| Current inventories | -18 | 45 |
| Other current and noncurrent assets | -49 | -378 |
| Accounts payable | - | 0 |
| Accrued legal and settlement expenses | -368 | -387 |
| Other current and noncurrent liabilities | 41 | 14 |
| Net cash (used in) provided by operating activities | -27 | 36 |
| Purchases of property and equipment | 66 | 29 |
| Purchases of in-process research and development and intangible assets | 1 | 2 |
| Acquisitions, net of cash acquired | 0 | 0 |
| Purchases of investments in debt securities | 20 | 17 |
| Sales of equity securities | 1 | - |
| Sales and maturities of debt securities | 19 | 117 |
| Other proceeds from investing activities | 0 | 0 |
| Net cash (used in) provided by investing activities | -66 | 69 |
| Proceeds from the issuance of common stock | 2 | 3 |
| Cash paid for repurchases of common stock | 11 | 173 |
| Proceeds from debt, net | 0 | 332 |
| Repayments of debt | 17 | 240 |
| Other | - | -2 |
| Transaction costs related to debt refinancing | 0 | - |
| Settlement of tax on equity awards | 5 | 22 |
| Net cash used in financing activities | -30 | -102 |
| Net (decrease) increase in cash and cash equivalents | -124 | 3 |
| Exchange differences | -1 | - |
| Cash and cash equivalents at beginning of period | 319 | 316 |
| Cash and cash equivalents at end of period | 195 | 319 |
Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. (INDV)